XML 44 R24.htm IDEA: XBRL DOCUMENT
v3.8.0.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION | 12 Months Ended
--- | ---
Mar. 31, 2018
Segment Reporting [Abstract] |
SEGMENT AND ENTERPRISE-WIDE INFORMATION | SEGMENT AND ENTERPRISE-WIDE INFORMATION We determine our reportable segments by first identifying our operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics. The Company’s reportable segments are as follows:
• | Japan
• | EMEA
• | North America Plasma
• | All Other
The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin. Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. During the first quarter of fiscal 2018, management changed the cost reporting structure such that a portion of corporate expenses were reclassified into the operating segments. Accordingly, the prior year numbers have been updated to reflect this reclassification. Selected information by business segment is presented below:
(In thousands) | 2018 |  | 2017 |  | 2016
Net revenues |  |  |  |  |
Japan | $ | 68,172 |  |  | $ | 74,695 |  |  | $ | 84,270 |
EMEA | 183,301 |  |  | 198,396 |  |  | 204,192 |
North America Plasma | 333,831 |  |  | 309,718 |  |  | 279,803 |
All Other | 324,013 |  |  | 316,771 |  |  | 342,249 |
Net revenues before foreign exchange impact | 909,317 |  |  | 899,580 |  |  | 910,515 |
Effect of exchange rates | (5,394 | ) |  | (13,464 | ) |  | (1,683 | )
Net revenues | $ | 903,923 |  |  | $ | 886,116 |  |  | $ | 908,832 |
(In thousands) | 2018 |  | 2017 |  | 2016
Segment operating income |  |  |  |  |
Japan | $ | 37,243 |  |  | $ | 39,892 |  |  | $ | 43,619 |
EMEA | 62,696 |  |  | 65,689 |  |  | 63,665 |
North America Plasma | 119,003 |  |  | 98,254 |  |  | 109,220 |
All Other | 128,945 |  |  | 127,834 |  |  | 127,493 |
Segment operating income | 347,887 |  |  | 331,669 |  |  | 343,997 |
Corporate operating expenses | (220,699 | ) |  | (211,481 | ) |  | (227,839 | )
Effect of exchange rates | 4,059 |  |  | (4,772 | ) |  | 3,546 |
Restructuring and turnaround costs | (44,125 | ) |  | (34,337 | ) |  | (42,185 | )
Deal amortization | (26,013 | ) |  | (27,107 | ) |  | (28,958 | )
Impairment of assets | (1,941 | ) |  | (73,353 | ) |  | (97,230 | )
Legal charges(1) | (3,011 | ) |  | — |  |  | — |
Contingent consideration income | — |  |  | — |  |  | 4,727 |
Operating income (loss) | $ | 56,157 |  |  | $ | (19,381 | ) |  | $ | (43,942 | )
(1) Reflects net impact of settlement charges associated with the fiscal 2017 voluntary whole blood collection kits recall.
(In thousands) | 2018 |  | 2017 |  | 2016
Depreciation and amortization |  |  |  |  |
Japan | $ | 486 |  |  | $ | 827 |  |  | $ | 774 |
EMEA | 4,464 |  |  | 4,255 |  |  | 5,146 |
North America Plasma | 16,060 |  |  | 13,022 |  |  | 12,944 |
All Other | 68,237 |  |  | 71,629 |  |  | 71,047 |
Total depreciation and amortization (excluding impairment charges) | $ | 89,247 |  |  | $ | 89,733 |  |  | $ | 89,911 |
(In thousands) | March 31, 2018 |  | April 1, 2017 |  | April 2, 2016
Long-lived assets(2) |  |  |  |  |
Japan | $ | 26,640 |  |  | $ | 21,412 |  |  | $ | 33,159 |
EMEA | 74,783 |  |  | 63,854 |  |  | 63,861 |
North America Plasma | 91,815 |  |  | 142,164 |  |  | 116,001 |
All Other | 138,918 |  |  | 96,432 |  |  | 124,613 |
Total long-lived assets | $ | 332,156 |  |  | $ | 323,862 |  |  | $ | 337,634 |
(2) Long-lived assets are comprised of property, plant and equipment.
Selected information by principle operating regions is presented below:
(Dollars in thousands) | 2018 |  | 2017 |  | 2016
Net Revenues |  |  |  |  |
United States | $ | 548,731 |  |  | $ | 522,686 |  |  | $ | 519,440 |
Japan | 67,319 |  |  | 79,266 |  |  | 81,411 |
Europe | 164,226 |  |  | 166,007 |  |  | 187,725 |
Asia | 115,127 |  |  | 109,858 |  |  | 111,758 |
Other | 8,520 |  |  | 8,299 |  |  | 8,498 |
Net revenues | $ | 903,923 |  |  | $ | 886,116 |  |  | $ | 908,832 |
(Dollars in thousands) | March 31, 2018 |  | April 1, 2017 |  | April 2, 2016
Long-lived assets(2) |  |  |  |  |
United States | $ | 236,603 |  |  | $ | 241,610 |  |  | $ | 231,744 |
Japan | 1,511 |  |  | 1,691 |  |  | 2,022 |
Europe | 13,696 |  |  | 12,952 |  |  | 18,672 |
Asia | 36,431 |  |  | 34,174 |  |  | 40,235 |
Other | 43,915 |  |  | 33,435 |  |  | 44,961 |
Total long-lived assets | $ | 332,156 |  |  | $ | 323,862 |  |  | $ | 337,634 |
(2) Long-lived assets are comprised of property, plant and equipment.
Our products are organized into four categories for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units, however, no other financial information is currently available on this basis. Net revenues by business unit are as follows:
(Dollars in thousands) | 2018 |  | 2017 |  | 2016
Plasma | 435,956 |  |  | 410,727 |  |  | 381,776 |
Blood Center | 284,902 |  |  | 303,890 |  |  | 355,108 |
Cell Processing | 107,562 |  |  | 105,376 |  |  | 112,483 |
Hemostasis Management | 75,503 |  |  | 66,123 |  |  | 59,465 |
Net revenues | $ | 903,923 |  |  | $ | 886,116 |  |  | $ | 908,832 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration